Clinical trials: Intravenous Infusions
Amyotrophic Lateral Sclerosis
ALS Phase II Study of NX210c
This study will investigate the efficacy, safety, tolerability and pharmacokinetics (PK) of multiple intravenous infusions of NX210c, at two dose levels, in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- SEALS (NCT06365216)
- Testing
- NX210c
- Where
- 16 sites in France
- Volunteers
- 80 people
- Sponsor
- Axoltis Pharma
Acute Lymphocytic Leukaemia
SAR3419 in Acute Lymphoblastic Leukemia
Primary Objective: Participants achieving an Objective Response Rate Secondary Objectives: Response duration Progression Free Survival Minimal residual disease Safety Pharmacokinetics
- Trial name
- MYRALL (NCT01440179)
- Testing
- SAR3419
- Where
- 11 sites in United States, France
- Volunteers
- 100 people
- Sponsor
- Sanofi
Relapsed/Refractory AML, Minimal Residual Disease Positive AML
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
The purpose of this First-in-Human Phase 1 study is to determine if AMG 330 given as a continuous IV infusion is safe and tolerable in adult subjects that have myeloid malignancies, and to determine the maximum tolerated dose…
- Conditions
- Relapsed/Refractory AML, Minimal Residual Disease Positive AML, Myelodysplastic Syndrome
- Trial name
- NCT02520427
- Testing
- AMG 330
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 95 people
- Sponsor
- Amgen
Stroke, Acute
Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke
The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.
- Trial name
- NCT00123305
- Testing
- Microplasmin
- Where
- 16 sites in Austria, Belgium and 1 more
- Volunteers
- 40 people
- Sponsor
- ThromboGenics
HIV Infections
PRO 140 by IV Administration in Adults With HIV-1 Infection
The purpose of this study is: 1. To assess and characterize the PK and PD of PRO 140 administered IV 2. To assess the antiviral activity of PRO 140 3. To assess the safety and tolerability of PRO 140
- Trial name
- NCT00613379
- Testing
- PRO 140
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- CytoDyn, Inc.
Pharmacokinetics in Healthy Adults
Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration
The proposed study aims to assess the time above MIC (4 mg/mL), and the pharmacokinetics/pharmacodynamics and bioavailability of 1 g ceftriaxone administered by constant rate subcutaneous infusion over 2 hours compared with 1 g…
- Trial name
- NCT02561442
- Testing
- ceftriaxone
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- scPharmaceuticals, Inc.
Carcinoma, Non-Small-Cell Lung
Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI
To collect information of safety in patients with unresectable advanced or recurrent non-small cell lung cancer who receive combination therapy of IMJUDO, IMFINZI and other platinum-based anti-cancer agents under actual use in…
- Trial name
- NCT05826366
- Where
- 28 sites in Japan
- Volunteers
- 296 people
- Sponsor
- AstraZeneca
Ebola Virus Infection
Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion
This is a phase 1, single-center, placebo-controlled, single-blind, first-in-human, single-ascending dose study with additional multiple-ascending dose cohorts in healthy male and female volunteers.
- Trial name
- NCT01518881
- Testing
- TKM-100201
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Arbutus Biopharma Corporation
Arrhythmia
Single Ascending Dose of GAP-134 as a 24-hour IV Infusion in Healthy Japanese Males
This is a study of GAP-134, an antiarrhythmic di-peptide. This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of GAP-134 after administration of ascending single intravenous (IV)…
- Trial name
- NCT00543946
- Testing
- GAP-134
- Where
- Japan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers
A clinical study to measure the effect of OP-101 after being administered intravenously in healthy volunteers.
- Trial name
- NCT03500627
- Testing
- OP-101
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Orpheris, Inc.
Crohn's Disease
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
This is a study to evaluate vedolizumab for injection (300 mg) as a safe and active treatment for Crohn's Disease in adults in China.
- Trial name
- NCT05837897
- Testing
- Vedolizumab IV
- Where
- 43 sites in China
- Volunteers
- 408 people
- Sponsor
- Takeda
Healthy
PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant
The hypothesis of this trial is that the test drug (Human Recombiant Epoetin - Blau) pharmacokinetics and pharmacodynamics parameters are similar to the comparator drug (Eprex ® - Janssen-Cilag) in healthy subjects following…
- Trial name
- NCT01685359
- Testing
- Epoetin Alfa
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Healthy
Clinical Trial to Assess the Safety, Tolerability and Pharmacokinetics of Cardiotrophin-1 in Healthy Volunteers
The general aim of the study is to determinate safety, tolerability and early pharmacokinetics of cardiotrophin.1 in healthy volunteers.
- Trial name
- NCT01334697
- Testing
- recombinant human cardiotrophin-1
- Where
- 2 sites in Spain
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Digna Biotech S.L.
Left Ventricle Function
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
- Trial name
- NCT00748982
- Testing
- AZD1305
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Osteosarcoma, Sarcoma
ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells.
- Trial name
- NCT05830123
- Testing
- HS-20093
- Where
- 11 sites in China
- Volunteers
- 170 people
- Sponsor
- Hansoh BioMedical R&D Company
Diagnostic Imaging, Neoplasms
Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
Visual assessment of diagnostic PET/CT (positron emission tomography/computed tomography) images obtained after a single intravenous injection of BAY94-9392 in patients with cancer or inflammation.
- Trial name
- NCT01103310
- Testing
- BAY94-9392
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Lantheus Biosciences Ltd.
Wet Age-Related Macular Degeneration
Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration
This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.
- Trial name
- NCT00503022
- Testing
- ACZ885
- Where
- 8 sites in Switzerland, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Novartis
Safety Issues
A Phase1 Study of VIB9600
Overall design: Single-center, randomized, blinded, placebo-controlled single- and multiple-ascending dose study in healthy adult subjects.
- Trial name
- NCT03621605
- Testing
- VIB9600
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amgen
Healthy
Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers
HF1K16 is an investigational pegylated liposome formulation of tretinoin for injection for the treatment of solid tumors through targeting myeloid derived suppressor cells (MDSCs).
- Trial name
- NCT05386823
- Testing
- HF1K16
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- HighField Biopharmaceuticals Corporation
Hereditary Angioedema (HAE)
Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)
The purpose of this study is to determine if an investigational treatment is safe and well tolerated when administered by intravenous (IV) infusion in Japanese subjects with HAE.
- Trial name
- NCT02865720
- Testing
- CINRYZE 500 U, CINRYZE 1000 U
- Where
- 10 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Shire